| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1From the Department of Ophthalmology, Royal Victoria Hospital, The Queen’s University of Belfast, Northern Ireland; the 2Massachusetts Eye and Ear Infirmary and 5The Children’s Hospital, Harvard Medical School, Boston, Massachusetts; the 3School of Biomedical Sciences, University of Ulster, Coleraine, Northern Ireland; the 4Scripps Research Institute, La Jolla, California; and 6Eyetech Pharmaceuticals, New York, New York.
PURPOSE. A critical event in the pathogenesis of diabetic retinopathy is the inappropriate adherence of leukocytes to the retinal capillaries. Advanced glycation end-products (AGEs) are known to play a role in chronic inflammatory processes, and the authors postulated that these adducts may play a role in promoting pathogenic increases in proinflammatory pathways within the retinal microvasculature.
METHODS. Retinal microvascular endothelial cells (RMECs) were treated with glycoaldehyde-modified albumin (AGE-Alb) or unmodified albumin (Alb). NF
B DNA binding was measured by electromobility shift assay (EMSA) and quantified with an ELISA. In addition, the effect of AGEs on leukocyte adhesion to endothelial cell monolayers was investigated. Further studies were performed in an attempt to confirm that this was AGE-induced adhesion by co-incubation of AGE-treated cells with soluble receptor for AGE (sRAGE). Parallel in vivo studies of nondiabetic mice assessed the effect of intraperitoneal delivery of AGE-Alb on ICAM-1 mRNA expression, NFB DNA-binding activity, leukostasis, and blood-retinal barrier breakdown.
RESULTS. Treatment with AGE-Alb significantly enhanced the DNA-binding activity of NFB (P = 0.0045) in retinal endothelial cells (RMECs) and increased the adhesion of leukocytes to RMEC monolayers (P = 0.04). The latter was significantly reduced by co-incubation with sRAGE (P < 0.01). Mice infused with AGE-Alb demonstrated a 1.8-fold increase in ICAM-1 mRNA when compared with control animals (P < 0.001, n = 20) as early as 48 hours, and this response remained for 7 days of treatment. Quantification of retinal NFB demonstrated a threefold increase with AGE-Alb infusion in comparison to control levels (AGE Alb versus Alb, 0.23 vs. 0.076, P < 0.001, n = 10 mice). AGE-Alb treatment of mice also caused a significant increase in leukostasis in the retina (AGE-Alb versus Alb, 6.89 vs. 2.53, n = 12, P < 0.05) and a statistically significant increase in breakdown of the blood-retinal barrier (AGE Alb versus Alb, 8.2 vs. 1.6 n = 10, P < 0.001).
CONCLUSIONS. AGEs caused upregulation of NFB in the retinal microvascular endothelium and an AGE-specific increase in leukocyte adhesion in vitro was also observed. In addition, increased leukocyte adherence in vivo was demonstrated that was accompanied by blood-retinal barrier dysfunction. These findings add further evidence to the thinking that AGEs may play an important role in the pathogenesis of diabetic retinopathy.
This article has been cited by other articles:
|
|
 |
|
  D. Skondra, K. Noda, L. Almulki, F. Tayyari, S. Frimmel, T. Nakazawa, I. K. Kim, S. Zandi, K. L. Thomas, J. W. Miller, et al. Characterization of Azurocidin as a Permeability Factor in the Retina: Involvement in VEGF-Induced and Early Diabetic Blood-Retinal Barrier Breakdown Invest. Ophthalmol. Vis. Sci., February 1, 2008; 49(2): 726 - 731. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Temm and J. H. Dominguez Microcirculation: nexus of comorbidities in diabetes Am J Physiol Renal Physiol, August 1, 2007; 293(2): F486 - F493. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Smith, D. Choi, T. J. Chipps, Y. Pan, D. O. Zamora, M. H. Davies, B. Babra, M. R. Powers, S. R. Planck, and J. T. Rosenbaum Unique Gene Expression Profiles of Donor-Matched Human Retinal and Choroidal Vascular Endothelial Cells Invest. Ophthalmol. Vis. Sci., June 1, 2007; 48(6): 2676 - 2684. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Kaji, T. Usui, S. Ishida, K. Yamashiro, T. C. B. Moore, J. Moore, Y. Yamamoto, H. Yamamoto, and A. P. Adamis Inhibition of Diabetic Leukostasis and Blood-Retinal Barrier Breakdown with a Soluble Form of a Receptor for Advanced Glycation End Products Invest. Ophthalmol. Vis. Sci., February 1, 2007; 48(2): 858 - 865. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-i. Yamagishi, K. Nakamura, T. Matsui, Y. Inagaki, K. Takenaka, Y. Jinnouchi, Y. Yoshida, T. Matsuura, I. Narama, Y. Motomiya, et al. Pigment Epithelium-derived Factor Inhibits Advanced Glycation End Product-induced Retinal Vascular Hyperpermeability by Blocking Reactive Oxygen Species-mediated Vascular Endothelial Growth Factor Expression J. Biol. Chem., July 21, 2006; 281(29): 20213 - 20220. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. R. Barile, S. I. Pachydaki, S. R. Tari, S. E. Lee, C. M. Donmoyer, W. Ma, L. L. Rong, L. G. Buciarelli, T. Wendt, H. Horig, et al. The RAGE Axis in Early Diabetic Retinopathy Invest. Ophthalmol. Vis. Sci., August 1, 2005; 46(8): 2916 - 2924. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. W. Stitt, C. McGoldrick, A. Rice-McCaldin, D. R. McCance, J. V. Glenn, D. K. Hsu, F.-T. Liu, S. R. Thorpe, and T. A. Gardiner Impaired Retinal Angiogenesis in Diabetes: Role of Advanced Glycation End Products and Galectin-3 Diabetes, March 1, 2005; 54(3): 785 - 794. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-L. Wautier and A. M. Schmidt Protein Glycation: A Firm Link to Endothelial Cell Dysfunction Circ. Res., August 6, 2004; 95(3): 233 - 238. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
